Nov. 13 at 1:09 PM
$CNMD 6-K 2025-11-13 On November 13, 2025, Clearmind Medicine (the “Company”), entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with investors for the purchase and sale of (i) 958,222 of the Company’s common shares, no par value (the “Common Shares”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,984,146 Common Shares, in a registered direct offering (the “Offering”) at a purchase price of
$0.20 per Common Share and
$0.1999 per Pre-Funded Warrant
https://app.quotemedia.com/data/downloadFiling?webmasterId=500&ref=319574045&type=HTML&symbol=CMND&cdn=01dc782b10f09cdd23fb273fa8e031fb&companyName=Clearmind+Medicine+Inc.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2025-11-13